drugset / Trial / NCT07379125
Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1
Recruiting
18 enrolled
Washington University School of Medicine
Phoenix Molecular Designs · collabSwim Across America · collabThe Foundation for Barnes-Jewish Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in participants with myelofibrosis (MF).The dose escalation portion utilizes a standard 3+3 design to evaluate two dose levels with an additional dose de-escalation portion to identify the recommended phase II dose (RP2D); subsequently, an additional 6 patients will be enrolled in the dose expansion portion evaluating the efficacy of PMD-026.
Timeline
- Start
- 2026-05-20
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PMD-026 | Unknown | — | Oral |